These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33226806)

  • 1. Stabilization Strategies for Linear Minigastrin Analogues: Further Improvements
    Klingler M; Hörmann AA; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
    J Med Chem; 2020 Dec; 63(23):14668-14679. PubMed ID: 33226806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.
    Klingler M; Decristoforo C; Rangger C; Summer D; Foster J; Sosabowski JK; von Guggenberg E
    Theranostics; 2018; 8(11):2896-2908. PubMed ID: 29896292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
    Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
    Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
    J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
    Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
    J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting.
    Grob NM; Häussinger D; Deupi X; Schibli R; Behe M; Mindt TL
    J Med Chem; 2020 May; 63(9):4484-4495. PubMed ID: 32302139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptor.
    Kolenc Peitl P; Tamma M; Kroselj M; Braun F; Waser B; Reubi JC; Sollner Dolenc M; Maecke HR; Mansi R
    Bioconjug Chem; 2015 Jun; 26(6):1113-9. PubMed ID: 25971921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo characterization of three 68Ga- and 111In-labeled peptides for cholecystokinin receptor imaging.
    Roosenburg S; Laverman P; Joosten L; Eek A; Rutjes FP; van Delft FL; Boerman OC
    Mol Imaging; 2012; 11(5):401-7. PubMed ID: 22954184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin.
    Laverman P; Roosenburg S; Gotthardt M; Park J; Oyen WJ; de Jong M; Hellmich MR; Rutjes FP; van Delft FL; Boerman OC
    Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):386-92. PubMed ID: 17934729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions.
    Grob NM; Schmid S; Schibli R; Behe M; Mindt TL
    J Med Chem; 2020 May; 63(9):4496-4505. PubMed ID: 32302130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates.
    Grob NM; Behe M; von Guggenberg E; Schibli R; Mindt TL
    J Pept Sci; 2017 Jan; 23(1):38-44. PubMed ID: 28054429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimerization results in formation of re-bindable metabolites: A proof of concept study with FSC-based minigastrin imaging probes targeting CCK2R expression.
    Summer D; Kroess A; Woerndle R; Rangger C; Klingler M; Haas H; Kremser L; Lindner HH; von Guggenberg E; Decristoforo C
    PLoS One; 2018; 13(7):e0201224. PubMed ID: 30059514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative.
    Ocak M; Helbok A; von Guggenberg E; Ozsoy Y; Kabasakal L; Kremser L; Decristoforo C
    Nucl Med Biol; 2011 Feb; 38(2):171-9. PubMed ID: 21315272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of CCK-2 receptor-expressing tumors using a radiolabeled divalent gastrin peptide.
    Sosabowski JK; Matzow T; Foster JM; Finucane C; Ellison D; Watson SA; Mather SJ
    J Nucl Med; 2009 Dec; 50(12):2082-9. PubMed ID: 19910426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies.
    von Guggenberg E; Rangger C; Sosabowski J; Laverman P; Reubi JC; Virgolini IJ; Decristoforo C
    Mol Imaging Biol; 2012 Jun; 14(3):366-75. PubMed ID: 21732165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
    Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin (111)In-radioligands.
    Kaloudi A; Nock BA; Lymperis E; Sallegger W; Krenning EP; de Jong M; Maina T
    Nucl Med Biol; 2015 Nov; 42(11):824-32. PubMed ID: 26300210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the binding and internalization properties of 12 DOTA-coupled and ¹¹¹In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607.
    Aloj L; Aurilio M; Rinaldi V; D'ambrosio L; Tesauro D; Peitl PK; Maina T; Mansi R; von Guggenberg E; Joosten L; Sosabowski JK; Breeman WA; De Blois E; Koelewijn S; Melis M; Waser B; Beetschen K; Reubi JC; de Jong M
    Eur J Nucl Med Mol Imaging; 2011 Aug; 38(8):1417-25. PubMed ID: 21523391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiolabelled CCK
    Novak D; Tomašič T; Krošelj M; Javornik U; Plavec J; Anderluh M; Kolenc Peitl P
    ChemMedChem; 2021 Jan; 16(1):155-163. PubMed ID: 32643833
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Rangger C; Klingler M; Balogh L; Pöstényi Z; Polyak A; Pawlak D; Mikołajczak R; von Guggenberg E
    Mol Pharm; 2017 Sep; 14(9):3045-3058. PubMed ID: 28728415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.